BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 32518016)

  • 1. Frailty is a determinant of suboptimal chemotherapy in women with advanced ovarian cancer.
    Narasimhulu DM; McGree ME; Weaver AL; Jatoi A; LeBrasseur NK; Glaser GE; Langstraat CL; Block MS; Kumar A
    Gynecol Oncol; 2020 Sep; 158(3):646-652. PubMed ID: 32518016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional not chronologic age: Frailty index predicts outcomes in advanced ovarian cancer.
    Kumar A; Langstraat CL; DeJong SR; McGree ME; Bakkum-Gamez JN; Weaver AL; LeBrasseur NK; Cliby WA
    Gynecol Oncol; 2017 Oct; 147(1):104-109. PubMed ID: 28734497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using an evidence-based triage algorithm to reduce 90-day mortality after primary debulking surgery for advanced epithelial ovarian cancer.
    Narasimhulu DM; Kumar A; Weaver AL; McGree ME; Langstraat CL; Cliby WA
    Gynecol Oncol; 2019 Oct; 155(1):58-62. PubMed ID: 31402165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
    Ma Y; Li Y; Cui H; Liang XD; Tang ZJ; Li XP; Zhao Y; Wei LH
    Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis.
    Ghirardi V; Moruzzi MC; Bizzarri N; Vargiu V; D'Indinosante M; Garganese G; Pasciuto T; Loverro M; Scambia G; Fagotti A
    Gynecol Oncol; 2020 Apr; 157(1):209-213. PubMed ID: 31952843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes in ovarian cancer patients receiving three versus more cycles of chemotherapy after neoadjuvant treatment and interval cytoreductive surgery.
    Kim JS; Liang MI; Prendergast EN; Alldredge J; Datta A; Hurteau JA; Kirschner CV; Rodriguez G; Vogel TJ; Brooks RA; Cass I; Cohen JG; Penner KR; Wang CE; Diaz Moore ES
    Int J Gynecol Cancer; 2019 Sep; 29(7):1156-1163. PubMed ID: 31352365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frailty based on the memorial Sloan Kettering Frailty Index is associated with surgical decision making, clinical trial participation, and overall survival among older women with ovarian cancer.
    Filippova OT; Tin AL; Alonso J; Vickers AJ; Tew WP; Gardner GJ; Sonoda Y; Roche KL; Zivanovic O; Chi DS; Shahrokni A
    Gynecol Oncol; 2021 Jun; 161(3):687-692. PubMed ID: 33773807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS).
    Au-Yeung G; Webb PM; DeFazio A; Fereday S; Bressel M; Mileshkin L
    Gynecol Oncol; 2014 Apr; 133(1):16-22. PubMed ID: 24680586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs of treatment for elderly women with advanced ovarian cancer in a Medicare population.
    Forde GK; Chang J; Ziogas A; Tewari K; Bristow RE
    Gynecol Oncol; 2015 Jun; 137(3):479-84. PubMed ID: 25866323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort study.
    Sivakumaran T; Mileshkin L; Grant P; Na L; DeFazio A; Friedlander M; Obermair A; Webb PM; Au-Yeung G;
    Gynecol Oncol; 2020 Jul; 158(1):47-53. PubMed ID: 32381362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of non-completion of intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer.
    Chambers LM; Son J; Radeva M; DeBernardo R
    J Gynecol Oncol; 2019 Nov; 30(6):e93. PubMed ID: 31576687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
    Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
    Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multivariate analysis of the prognostic impact of tumor burden, surgical timing and complexity after complete cytoreduction for advanced ovarian cancer.
    Angeles MA; Rychlik A; Cabarrou B; Spagnolo E; Guyon F; Pérez-Benavente A; Gil-Moreno A; Siegrist J; Querleu D; Mery E; Gladieff L; Hernández A; Ferron G; Martinez A
    Gynecol Oncol; 2020 Sep; 158(3):614-621. PubMed ID: 32709536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of the relative dose intensity of chemotherapy in primary treatment of epithelial ovarian cancer.
    Fauci JM; Whitworth JM; Schneider KE; Subramaniam A; Zhang B; Frederick PJ; Kilgore LC; Straughn JM
    Gynecol Oncol; 2011 Sep; 122(3):532-5. PubMed ID: 21658751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. When Less Is More: Minimally Invasive Surgery Compared with Laparotomy for Interval Debulking After Neoadjuvant Chemotherapy in Women with Advanced Ovarian Cancer.
    Brown J; Drury L; Crane EK; Anderson WE; Tait DL; Higgins RV; Naumann RW
    J Minim Invasive Gynecol; 2019; 26(5):902-909. PubMed ID: 30240899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
    Yao SE; Tripcony L; Sanday K; Robertson J; Perrin L; Chetty N; Land R; Garrett A; Obermair A; Nascimento M; Tang A; Jagasia N; Singh P; Nicklin J
    Int J Gynecol Cancer; 2020 Dec; 30(12):1935-1942. PubMed ID: 33122245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV).
    Glasgow MA; Yu H; Rutherford TJ; Azodi M; Silasi DA; Santin AD; Schwartz PE
    J Surg Oncol; 2013 Feb; 107(2):195-200. PubMed ID: 22648987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study.
    Gao Y; Li Y; Zhang C; Han J; Liang H; Zhang K; Guo H
    J Ovarian Res; 2019 Sep; 12(1):85. PubMed ID: 31519183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.
    Bian C; Yao K; Li L; Yi T; Zhao X
    Arch Gynecol Obstet; 2016 Jan; 293(1):163-168. PubMed ID: 26198168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frailty in ovarian cancer identified the need for increased postoperative care requirements following cytoreductive surgery.
    Yao T; DeJong SR; McGree ME; Weaver AL; Cliby WA; Kumar A
    Gynecol Oncol; 2019 Apr; 153(1):68-73. PubMed ID: 30612784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.